Mineralys’ Positive CKD Data Expands the Investment Case for Lorundrostat
Positive Phase 2 CKD data may broaden lorundrostat’s commercial potential and sharpen investor interest in Mineralys Therapeutics.
Lumentum Shares Jump on Reported Marvell Acquisition Talks
Lumentum shares rose after a report said Marvell was in advanced talks to acquire the optical-compon…
Kymera Therapeutics Sets Up Year-End Catalyst With KT-621 Data on Deck
Kymera’s third-quarter update pairs positive KT-579 Phase 1 results with a year-end 2026 KT-621 Phas…
Iovance Stock Jumps as Lifileucel Combination Delivers 62.5% Response Rate
Iovance’s frontline melanoma data could broaden lifileucel’s opportunity, but the result is not yet …
Wendy’s Jumps on Reported $1.4 Billion Trian Takeover Offer
Wendy’s shares jumped after a report of a $1.4 billion Trian takeover offer, putting deal certainty …
Cullinan Therapeutics’ FDA IND Clearance Moves Velinotamig Toward Global Autoimmune Trials
Cullinan Therapeutics’ FDA IND clearance moves velinotamig into global clinical development for auto…
Genmab ADR Surges 16.8% as Biotech Traders Revisit Catalyst and M&A Speculation
Genmab’s GMAB ADR surged 16.8% in morning trading, putting M&A speculation, catalysts and biotech pe…
Eli Lilly’s Retatrutide Data Raises Stakes in the GLP-1 Drug Race
New retatrutide trial data may strengthen Eli Lilly’s position in the GLP-1 market, while raising ex…
GE Vernova’s $9 Billion Trench Deal Puts Grid Investment and Raised Outlook in Focus
GE Vernova’s $9 billion Trench acquisition highlights grid-equipment demand as AI-related power infr…
Wendy’s Shares Jump on Reported $1.4 Billion Trian Takeover Offer
Wendy’s shares moved higher after a report that Nelson Peltz’s Trian Partners offered $1.4 billion t…